Medicinova(JP:4875)
¥225.00-1.00 (-0.44%)
JP:4875
Medicinova financials statements
¥225.00
At close:-1.00 (-0.44%)
Medicinova (4875) Ratios
0 Followers
Medicinova Ratios
JP:4875's free cash flow for Q2 2026 was $-1.92M. For the 2026 fiscal year, JP:4875's free cash flow was increased by $0.00 and operating cash flow was $-1.92M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.16 | 13.88 | 15.61 | 18.51 | 25.42 |
| Quick Ratio | 8.16 | 13.88 | 15.61 | 18.51 | 25.42 |
| Cash Ratio | 8.11 | 13.64 | 15.55 | 5.81 | 25.21 |
| Solvency Ratio | -2.98 | -3.27 | -2.20 | -3.59 | -2.71 |
| Operating Cash Flow Ratio | -2.58 | -3.60 | -2.27 | -4.05 | -3.31 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 26.97M | $ 37.70M | $ 47.28M | $ 55.07M | $ 68.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.06 | 1.06 | 1.06 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Net Debt to EBITDA | 2.56 | 3.64 | 5.14 | 1.22 | 6.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 7.58% | 0.00% | 100.00% | 0.00% | 100.00% |
| EBIT Margin | -2927.32% | 0.00% | -990.03% | 0.00% | -253.02% |
| EBITDA Margin | -2922.41% | 0.00% | -988.00% | 0.00% | -252.38% |
| Operating Profit Margin | -3242.47% | 0.00% | -990.03% | 0.00% | -253.02% |
| Pretax Profit Margin | -2927.32% | 0.00% | -856.85% | 0.00% | -250.94% |
| Net Profit Margin | -2928.78% | 0.00% | -857.15% | 0.00% | -251.00% |
| Continuous Operations Profit Margin | -2928.78% | 0.00% | -857.15% | 0.00% | -251.00% |
| Net Income Per EBT | 100.05% | 100.05% | 100.04% | 100.02% | 100.03% |
| EBT Per EBIT | 90.28% | 87.13% | 86.55% | 96.16% | 99.18% |
| Return on Assets (ROA) | -26.31% | -19.78% | -12.93% | -18.97% | -11.59% |
| Return on Equity (ROE) | -28.85% | -21.05% | -13.74% | -20.03% | -12.11% |
| Return on Capital Employed (ROCE) | -31.77% | -23.95% | -15.72% | -20.61% | -12.08% |
| Return on Invested Capital (ROIC) | -31.63% | -23.87% | -15.66% | -20.57% | -12.06% |
| Return on Tangible Assets | -38.45% | -26.64% | -16.53% | -23.54% | -13.88% |
| Earnings Yield | -18.67% | -10.73% | -11.65% | -13.99% | -7.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.13 | 0.00 | 1.61 | 0.00 | 4.58 |
| Asset Turnover | 0.01 | 0.00 | 0.02 | 0.00 | 0.05 |
| Working Capital Turnover Ratio | 0.01 | 0.00 | 0.02 | 0.00 | 0.06 |
| Cash Conversion Cycle | -602.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 602.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.20 | -0.22 | -0.15 | -0.26 | -0.19 |
| Free Cash Flow Per Share | -0.20 | -0.22 | -0.15 | -0.26 | -0.19 |
| Dividend Paid and CapEx Coverage Ratio | -3383.95 | -11891.58 | -348.89 | -2577.16 | -326.52 |
| Capital Expenditure Coverage Ratio | -3383.95 | -11891.58 | -348.89 | -2577.16 | -326.52 |
| Operating Cash Flow Coverage Ratio | -50.48 | -54.93 | -34.41 | -18.96 | -11.35 |
| Operating Cash Flow to Sales Ratio | -23.95 | 0.00 | -7.43 | 0.00 | -2.32 |
| Free Cash Flow Yield | -15.27% | -10.33% | -10.13% | -12.85% | -7.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.46 | -9.13 | -8.58 | -7.15 | -12.85 |
| Price-to-Sales (P/S) Ratio | 156.89 | 0.00 | 73.57 | 0.00 | 32.26 |
| Price-to-Book (P/B) Ratio | 1.55 | 1.96 | 1.18 | 1.43 | 1.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.55 | -9.68 | -9.87 | -7.78 | -13.84 |
| Price-to-Operating Cash Flow Ratio | -6.55 | -9.68 | -9.90 | -7.79 | -13.88 |
| Price-to-Earnings Growth (PEG) Ratio | -1.26 | -0.26 | 0.21 | -0.19 | 0.40 |
| Enterprise Value Multiple | -2.81 | -5.70 | -2.31 | -5.66 | -5.85 |
| Enterprise Value | 33.66M | 62.83M | 22.79M | 82.72M | 59.63M |
| EV to EBITDA | -2.81 | -5.70 | -2.31 | -5.66 | -5.85 |
| EV to Sales | 82.17 | 0.00 | 22.79 | 0.00 | 14.77 |
| EV to Free Cash Flow | -3.43 | -5.90 | -3.06 | -6.40 | -6.34 |
| EV to Operating Cash Flow | -3.43 | -5.90 | -3.07 | -6.41 | -6.36 |
| Tangible Book Value Per Share | 0.55 | 0.78 | 0.98 | 1.14 | 1.43 |
| Shareholders’ Equity Per Share | 0.85 | 1.07 | 1.27 | 1.43 | 1.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.01 | 0.00 | 0.02 | 0.00 | 0.08 |
| Net Income Per Share | -0.24 | -0.23 | -0.17 | -0.29 | -0.21 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.87 | 0.96 | 0.99 |
| Research & Development to Revenue | 17.47 | 0.00 | 5.66 | 0.00 | 2.01 |
| SG&A to Revenue | 15.04 | 0.00 | 4.98 | 0.00 | 1.36 |
| Stock-Based Compensation to Revenue | 2.02 | 0.00 | 0.71 | 0.00 | 0.43 |
| Income Quality | 0.82 | 0.96 | 0.87 | 0.92 | 0.93 |
Currency in USD
